SEC Form DFiling only, no announcement found
BioLineRx, based in Modi'in, L3, reported $3,750,000 sold in a private offering of options or warrants, with the first sale on August 27, 2026, in a Form D filed with the SEC on September 9, 2026. The filing says 1 investor has already invested.
Legal name on the filing: BioLineRx Ltd.. Formerly BioLineRX, Ltd..
| Amount sold | $3,750,000Basis: Form D total amount sold, as of the filing of September 9, 2026. Not the announced round size. |
|---|---|
| Total offering | $3,750,000The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $0 |
| Securities offered | Option, warrant or other right to acquire another security; Security to be acquired upon exercise of option, warrant or other right |
| Exemption claimed | Rule 506(b) |
| Date of first sale | August 27, 2026 |
| Investors already invested | 1 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | Modi'in, L3 |
| Jurisdiction of incorporation | ISRAEL |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 1498403 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Philip A. Serlin | Executive OfficerChief Executive Officer | None linked |
| Mali Zeevi | Executive OfficerChief Financial Officer | None linked |
| Ella Sorani | Executive OfficerChief Development Officer | None linked |
| Aharon Schwartz | Director | None linked |
| Rami Dar | Director | None linked |
| BJ Bormann | Director | None linked |
| Raphael Hofstein | Director | None linked |
| Avraham Molcho | Director | None linked |
| Sandra Panem | Director | None linked |
| Shaoyu Yan | Director | None linked |
| Gal Cohen | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Sep 9, 2026 | D (original) | $3,750,000 | $3,750,000 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "BioLineRx: SEC Form D deal record", https://vcbeast.com/deals/biolinerx-form-d-2026-08-27. Source: SEC EDGAR, accession 0001178913-26-004469.